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Xavier Calvet, MD1,2,4
INTRODUCTION: Helicobacter pylori-infected individualsmay present low-density infection, undetectable by conventional
tests such as histology, rapid urease test, or urea breath test. Droplet digital polymerase chain reaction
(ddPCR) ismore sensitive thanother polymerasechain reactionmethods.Weaimed to evaluate the ability
of ddPCR to detect H. pylori infection in patients diagnosed as negative by conventional tests.
METHODS: Dyspeptic patients (n5 236) were tested forH. pylori by histology, urea breath test, and rapid urease test.
Patients were classified as having 3 positive (n5 25, control group), 2 positive (n5 12), one positive (n5
41), or zero positive (n5158) diagnostic tests.DNAwasextracted fromgastric biopsies. TriplicateddPCR
testing for each of the 16S rDNA, ureA, and vacA(s) genes was performed using a QX200 ddPCR system
(Bio-Rad). A gene was considered positive when detected by at least 2 of 3 repeated ddPCRs. H. pylori
positivity was defined as having 2 or more positive genes.
RESULTS: All the biopsies of the control patients were positive for all 3 16S rDNA, ureA, and vacA(s) genes.H. pylori
infectionwasdetected in57 (36%),22 (54%), and9 (75%)patientswith zero, 1, and2positive diagnostic
tests, respectively. The density of infection was 5, 121, 599, and 3,133 copies of H. pylori genome
equivalents for patients with zero, 1, and 2 of 3 positive test results and for the control group, respectively.
DISCUSSION: ddPCR detected low-density “occult” H. pylori infection in a significant proportion (36%) of patients
diagnosed as negative by conventional methods. The number of conventional positive tests was related
to the density of infection.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A290
Clinical and Translational Gastroenterology 2020;11:e00184. https://doi.org/10.14309/ctg.0000000000000184
INTRODUCTION
H. pylori infection is associated with dyspeptic symptoms, peptic
ulcer, and gastric cancer. Infection is present in more than half of
the human population (1). Its mortality is high, mostly related to
gastric cancer; in fact, it is responsible for 783,000 deaths each year
and is the third cause of cancer death worldwide (2). Adequate
diagnosis and treatment of the infection are curative for peptic
ulcer and may prevent the development of gastric cancer (3).
Several conventional methods are available for the detection of
active H. pylori infection. The main noninvasive tests are the urea
breath test and the stool H. pylori antigen test (4). Invasive tests
require endoscopy to obtain tissue biopsies and include rapid
urease test, culture, and histological examination (5,6). Among all
the available tests, urea breath test and histology are considered the
most accurate. The efficacy of all these tests is limited by situations
or treatments that decrease bacterial density, such as upper gas-
trointestinal bleeding or treatmentwith antibiotics orprotonpump
inhibitors. Invasive tests are also limited by the possibility of
sampling error because of the irregular distribution of bacteria
throughout the stomach (7,8).
Many previous studies suggest that subclinical infection with
H. pylori (i.e., when infection density is below the detection
threshold of conventional diagnostic tests [DT])may be a frequent
event. One of the first reports of “occult” infection dates from 2006
when, in a study aimed to describe the bacterial gastric diversity of
23 healthy individuals, Bik et al. found thatH. pyloriwas detectable
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by molecular methods in 7 of 11 patients identified as negative by
conventional tests (9). Currently, low-density infection has been
described in patients on antisecretory or antibiotic treatment
(10,11), in patients with extensive atrophy of the gastric mucosa
and/or intestinal metaplasia (12), in gastric MALT lymphoma
(13,14), and in peptic ulcer bleeding (15).
Having accurate DT is fundamental to ensuring quality of care
by avoidingunnecessary treatments and/or theunderuse of effective
therapies. For infectious diseases, molecular DT may help improve
the quality of results provided by monoclonal tests, microbiology
culture, or histology. Polymerase chain reaction (PCR), for instance,
has a sensitivity and specificity close to 100% for the detection ofH.
pylori in patients with chronic gastritis or nonpeptic ulcer bleeding
(16,17). Moreover, previous studies suggest that PCR is capable of
detecting low-density infection in a significant number of patients
with dyspepsia compared with conventional techniques (18,19).
More recently, a study of histologically H. pylori-negative gastritis
showed that 49% of patients with chronic mucosal inflammation
were positive by PCR (20). Finally, PCR was able to detect active
infection even in a proportion of healthy individuals diagnosed as
negative for H. pylori by conventional tests (21,22).
Furthermore, highly sensitive molecular techniques can help
detectingH. pylori in clinical settings such as peptic ulcer bleeding,
gastric cancer, orMALT lymphoma inwhich diagnosis ofH. pylori
is important but difficult to achieve. In this context, we demon-
strated that real-time PCR improves the detection of H. pylori in
paraffin samples obtained during an episode of upper gastroin-
testinal bleedingdue topepticulcer (23). In addition, there seems to
be an association between the density of infection and the virulence
of the strain, with virulent strains having the lowest density (24).
This latter finding also suggests that low-density infection may be
related to more virulent strains and so may not be innocuous.
The latest commercially available refinement inPCRtechnology is
digital PCR (dPCR) (25). dPCR is a quantitative technology that
shows increased sensitivity when compared with conventional or
real-time PCR methods while maintaining specificity (26,27). dPCR
has proved to be useful for the detection of infectious agents in a va-
riety of sample types and, specifically, in thedetection andgenotyping
of resistance genes inH.pylori infection (28–30) and todetermine the
role of CYP219 polymorphisms in triple therapy efficacy (31).
Droplet digital PCR (ddPCR) is a method for performing dPCR
that is based on the generation of water-oil emulsion droplets. In
ddPCR, the PCR reaction of an individual sample is fractionated into
thousands of droplets (20,000) and subjected to end point PCR. Am-
plification of the templatemolecules occurs in each individual droplet,
and positive droplets are counted using a fluorescence detector.
In this study, our aim was to evaluate the presence of low-
density H. pylori infection in dyspeptic patients diagnosed as
negative by rapid urease test, urea breath test, and/or histology
using highly sensitive ddPCR.
PATIENTS AND METHODS
Study subjects
Outpatients sent to the endoscopy unit of the Hospital Universitari
Parc Tauĺı for dyspeptic symptoms from 2006 to 2014 were pro-
spectively recruited for our study. Patientswerecontactedbefore the
endoscopy. Those who agreed to participate in the study were
instructed to avoid all antisecretory drugs including proton pump
inhibitors in the 2 weeks before the endoscopy. Patients who were
unable to stop antisecretory drugs, those who had received anti-
biotics in the 4weeks before the endoscopy, and thosewith previous
H. pylori treatment were excluded. Before the endoscopy, the pa-
tient provided signed informed consent, and urea breath test was
performed.During endoscopy, 4 antral biopsieswere obtained: 2 for
histology, one for the urease test and culture, and one formolecular
analysis. The study was performed in accordance with the Decla-
ration of Helsinki and was approved by the ethics committee of the
Hospital Universitari Parc Tauĺı (Id. number 2015611).
Conventional DT
TheDT (histology, rapid urease test, urea breath test, and ddPCR)
were performed by technicianswhowere unaware of the results of
the other assessments.
The urea breath test was performed with the UBiTest 100 mg
(Otsuka Pharmaceutical Europe, Barcelona, Spain) in accordance
with the manufacturer’s specifications. A basal breath sample was
collected by blowing into a specially designedbag.After this, patients
took a pill of 100mgof 13C-labeled urea in 100mLofwater andfilled
a secondbreath bag 20minutes later. The sampleswere immediately
processed by nondispersive infrared spectrophotometry (POCo-
neTM Infrared Spectrophotometer, Otsuka Pharmaceutical, Tokyo,
Japan). In accordance with the manufacturer’s specifications, an
increase in the proportion 13C/12C (13CO2 (%)) of 2.5% ormore after
urea intake was considered as indicative of H. pylori infection.
Rapid urease test was performed aftermucosal sampling using the
Jatrox-HP test (CHR Heim Arzneimittel GmbH, Darmstadt, Ger-
many) and was read according to the manufacturer’s specifications.
For histology, biopsies were collected in formalin, stained with
Giemsa, and then evaluated by 2 pathologists specialized in digestive
disease. The pathologists were blinded to the results of the other DT.
H. pylori detection by ddPCR
DNA from the endoscopic biopsies was isolated with MasterPure
DNApurification kit (Epicentre,Madison,WI). IsolatedDNAwas
quantified with a QuantiFluor-P Fluorometer Quantus NGS
(Promega Corporation, Madison, WI), and the concentration was
adjusted to 50 ng/mL with TE Buffer Low EDTA Ultrapure, USB
(USB Corporation Cleveland, OH).
TaqMan hydrolysis probe assays were used to amplify the
fragments of the 16S ribosomal ribonucleic acid (rRNA) and ureA
genes of H. pylori. The intercalating EvaGreen assay was used to
amplify the vacA gene (s segment) ofH. pylori. Primers and probes
used to amplify the target genes are listed in Table 1, Supplemen-
tary Digital Content 1, http://links.lww.com/CTG/A290.
The ddPCR conditions performed using the QX200 Droplet
Digital PCR System (Bio-Rad, Pleasanton, CA) are summarized in
the supplementary material file, http://links.lww.com/CTG/A290.
The results of ddPCR were generated using QX200 Droplet
Reader (Bio-Rad) and analyzed using QuantaSoft software version
1.7.4.0917 (Bio-Rad). Each of the 3 16S rRNA, ureA, and vacA
geneswere amplified in triplicate by ddPCR.AddPCRreactionwas
considered positive if one or more droplets were positive for Eva-
Green reactions and/or TaqMan reactions.
Tominimize false positive results, we set the restrictive criteria.
A biopsywas considered positive for a given gene when at least 2 of
the 3 replicateswerepositive, andH.pylori infectionwas considered
present only if 2 or all of the 3 genes tested were positive ddPCRs.
Human b-actin amplification
The quality of the DNA isolated from the biopsy specimens was
confirmed by an initial PCR. We used PCR on each DNA extract








to amplify a 83 bp fragment from the b-actin gene region (ACTB
gene, Prime Time qPCR Assay, IDT, Coralville, IA).
Bacterial strains
To evaluate the specificity of the technique for vacA (s), ureA, and
16S rRNA, 11 bacterial species were used, obtained either from the
clinical isolates of Staphylococcus epidermidis,Corynebacteriumsp.,
Proteus sp., Candida albicans, and Neisseria meningitidis or from
theAmerican Type Culture Collection (ATCC) (Rockville,MD) of
Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli,
Staphylococcus aureus, Streptococcus pneumoniae, and Haemo-
philus influenzae. Strains J99 and 26695 of H. pylori were used as
a positive control.
Data and statistical analysis
The mean number ofH. pylori copies of genome equivalents were
compared across all groups with a Kruskal-Wallis test, followed by
Dunn post hoc tests. Statistical analyses were performed using
GraphPad Prism 6 (La Jolla) and Microsoft Excel 2010 (Microsoft
Corp). Significance was set at P, 0.05.
RESULTS
Study subjects
A total of 634 dyspeptic patients were initially recruited. Sixty-one
patients with some DT not performed were excluded. Of the
remaining 573 patientswith 3DTperformed, 322were negative for
some or all tests. In this group, 111 patients lacking clinical data (n
5 35) or insufficient biopsy sample (n5 34) were excluded aswere
patients diagnosed with intestinal metaplasia, lymphocytic gastri-
tis, neuroendocrine tumor, or hyperplastic polyps (n5 42). Of the
251 patients with all positive DT, 25 were randomly selected as
a positive control group.
Finally, 236 patients with dyspeptic symptoms who had valid
results of 3 conventional DT were selected for the molecular
analysis. Patients were classified as having 3 positive (n 5 25,
control group), 0 positive (n 5 158), 1 positive (n 5 41), or 2
positive results (n 5 12) by conventional DT (Figure 1). Patient
characteristics, including endoscopic and histological diagnoses,
are shown in Table 1.
Validation of PCR assays
All the antral biopsy specimens from the 25 positive controls were
positive on all 3 PCR assays. On the other hand, all samples were
positive for human b-actin amplification, indicating that no PCR
inhibitors were present.
Species specificity of the PCR assays
All non-Helicobacter species were negative for the 3 genes am-
plified (vacA, ureA, and 16S). The 2 strains of H. pylori were
positive for all the 3 genes analyzed.
H. pylori detection frequency and copies of genome equivalents
quantified by ddPCR
H. pylori infection was detected by ddPCR in 57 (36%) patients
with zero positive DT, in 22 (54%) with one positive DT, and in 9
(75%) with two positive DT (Table 2). The distribution frequency
of the amplified genes is shown in Table 2. Individual results of the
triplicate ddPCR for each are shown in Figure 2 andTables 2 and 3,
Supplementary Digital Content 1, http://links.lww.com/CTG/
A290.All thebiopsies of the three positiveDTcontrol patientswere
positive for 16S rDNA, ureA, and vacA(s) genes.
The number of conventional positive tests was related to the
density of the infection (Figure 3). The density of the infection in
the three positiveDTcontrol groupwas 1,883 103, 1,113 103, and
6,40 3 103 copies of H. pylori genome equivalents for vacA(s),
ureA, and 16S rRNA, respectively. The infection density then de-
creasedprogressively by3orders ofmagnitudedown to;10 copies
in the zeropositiveDTgroup (Figure 3 andTable 4, Supplementary
Digital Content 1, http://links.lww.com/CTG/A290). These dif-
ferences in infection density were significant for each of the groups
when compared with the zero positive DT samples.
Role of the histological findings for detecting “occult”
H. pylori infection
Chronic active gastritis (mucosal neutrophil infiltration) was
found in 24 of 25 patients with three positive DT (96%) and in
only 4 of 158 patients with zero positive DT. As expected,
chronic active gastritis increased proportionally with the
number of positive DT: 9 of 41 patients with one positive DT
Figure 1. Study patients’ flow diagram. DT, diagnostic tests.
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(22%) and 9 of 12 patients with two positive DT (75%) (Table 1).
Neutrophil infiltrate was, however, not useful for diagnosing
occult infection. Chronic active gastritis was present in only 2 of
57 patients with zero negative DT and Hp positive by ddPCR
(4%) and in 2 of 101 patients with negative ddPCR (2%) (see
Table 4, Supplementary Digital Content 1, http://links.lww.
com/CTG/A290).
Among patients with positive ddPCR, lymphoid follicles were
present in 11 (19%), 12 (55%), and 6 (67%) patients with zero,
one, or two positive DT. Corresponding figures in patients neg-
ative by ddPCR were 18 (18%), 5 (26%), and 0, respectively (see
Tables 5 and 6, Supplementary Digital Content 1, http://links.
lww.com/CTG/A290).
Finally, H. pylori detection by ddPCR vs individual DT is
summarized in Table 7, Supplementary Digital Content 1, http://
links.lww.com/CTG/A290.
DISCUSSION
In this study, we found that ddPCR detects “occult” H. pylori in
a significant proportion (36%) of dyspeptic patients diagnosed as
negative by 3 conventional methods. The prevalence of infection in
patients with 1 or 2 positive tests was even higher, at 49% and 75%,
respectively. Thus, ddPCR seems to be more sensitive than conven-
tional tests. In addition, because it is a quantitative method, we were
able to quantify the density of the infection. Quantification indicated
thatH. pylori escapes conventionalDTwhen the bacterial load is low;
in fact, we found a clear linear correlation between the bacterial
density and the number of positive conventional tests (Figure 2).
Several authors suggest that PCR-based diagnosis can be con-
sidered a gold standard, provided that specificH. pylori primers are
used to targetmore than one conserved gene (32–34). In our case, to
avoid false positive results, ddPCR positivity was determined on the
amplification of 3 specificH. pylori genes, each of them in triplicate.
Table 1. Patient characteristics
0 DT Hp(1) (n5 158) 1 DT Hp(1) (n 5 41) 2 DT Hp(1) (n5 12) 3 DT Hp(1) (n5 25)
Gender (male/female) (n) 55/103 17/24 3/9 14/11
Age (mean 6 SD) 47 6 14 49 6 14 50 6 18 476 14
Endoscopic diagnosis (n):
Normal 128 39 8 15
Duodenal ulcer/erosive duodenitis 21 2 2 6
Gastric ulcer 1 0 1 0
Esophagitis (LA A or B/LA C or D) 2/1 0 0 2/2
Other 5 0 1 0
Histological diagnosis (n):
Gastritis (no/yes/Nd) 11/144/3 3/38/0 0/12/0 0/25/0
Gastritis activity (no/yes/Nd) 150/4/4 32/9/0 3/9/0 1/24/0
Gastritis severity (0/1/2/Nd) 12/141/2/3 3/35/3/0 2/7/3/0 0/15/10/0
Lymphoid follicle (no/yes/Nd) 120/29/9 24/17/0 4/6/2 8/15/2
Helicobacter pylori 0 4 8 25
Metaplasia/atrophy 0/1 0/3 0/0 0/0
DT, diagnostic tests; LA, Los Angeles esophagitis classification; Nd, no data; mild (A or B) or severe (C or D).
Table 2. Distribution frequency of the amplified genes by ddPCR
No. of Hp(1) genes
ddPCR positive for Hp (n(%))
Hp gene 0 DT Hp(1) (158 patients) 1 DT Hp(1) (41 patients) 2 DT Hp(1) (12 patients)
1 vacA (s) 54 (34%) 30 (73%) 9 (75%)
ureA 76 (48%) 23 (56%) 9 (75%)
16S 59 (37%) 22 (54%) 11 (92%)
2 vacA(s)-ureA 38 (24%) 20 (49%) 9 (75%)
vacA(s)-16S 38 (24%) 20 (49%) 9 (75%)
ureA-16S 47 (30%) 20 (49%) 9 (75%)
3 vacA-ureA-16S 33 (21%) 19 (46%) 9 (75%)
2 or 3 2 or 3 ddPCR Hp (1) 57 (36%) 22 (49%) 9 (75%)
ddPCR, droplet digital polymerase chain reaction; DT, diagnostic tests.








In addition,we selectedprimers that showedaveryhigh specificity in
previous publications (23,35). Therefore, our study suggests that
ddPCR may be a useful alternative for detecting H. pylori infection,
especially for patients with very low-degree, “occult” infection. In
fact, the results suggest that persistent low-density infection may
remain undetected in a proportion of patients submitted to endos-
copy for dyspepsia. The potential causal role of the infection in these
symptoms, however, remains to be determined.
Standard tests are suboptimal in certain clinical situations such as
MALT lymphoma, peptic ulcer bleeding, or extensive atrophy.
Several reports have indicated the presence ofH. pylori at low levels
in these clinical settings. For example, Raderer et al. (14) reported 6
patients with gastric MALT lymphoma with negative results for all
H. pylori conventional tests who presented complete resolution of
the disease after H. pylori treatment; the authors attributed this
finding to “occult” infection. In addition, Guell et al. (15) reported
that 79% of the patients with peptic ulcer bleeding who tested neg-
ative for H. pylori during the bleeding episode had active infection,
which was only detected when the tests were repeated a few weeks
after the episode. Our group previously reported that real-time PCR
detects H. pylori in more than two-thirds of histology-negative
samples from biopsies obtained during an episode of bleeding (23)
and in 27% of histology-negative samples from dyspeptic patients
with a “false positive” urea breath test (36). The prevalence and
relevance of “occult” H. pylori infection in dyspeptic patients or in
those with ulcer are currently unknown. It is possible, for example,
that “occult” infection may account for a proportion of idiopathic
peptic ulcers, an entity that seems to be increasingly frequent
worldwide (37). It may be worth investigating the prevalence of
“occult” infection in these cases. ddPCR examinations in the long-
term studies after eradication treatment would also be of interest.
Apart from MALT lymphoma, peptic ulcer bleeding, and
gastric atrophy, a growing body of evidence indicates that occult
infection may pass undetected after one or more of the con-
ventional tests in dyspeptic patients without these conditions,
and even in healthy volunteers. In a study of the gastric
microbiota of 23 healthy individuals, Bik et al. (21) analyzed
H. pylori infection by rapid urease test, histology, culture, se-
rology, and 16S rRNA sequencing and detected H. pylori in-
fection in 12 individuals by conventional tests (52%) and in 19 of
the 23 by molecular tests (83%). Kiss et al. (20) showed that
approximately 50% of histological gastritis and H. pylori-neg-
ative are PCR positive. Some authors suggest that patients with
chronic active gastritis in the absence of visibleH. pylori should
be considered as infected individuals in whom H. pylori has
temporarily disappeared from the mucosa because of PPI or
antibiotic use (38). This topic remains, however, unclear. Ana-
lyzing epidemiological data, the same authors also suggested
that chronic active gastritis in the absence of H. pylori may be
a distinct entity with an as yet unknown etiologic agent (39). As
an alternative, occult H. pylori infection may help explain this
situation. Conversely, even in the absence of active gastritis,
H. pylori has been detected by immunohistochemistry (40) or
histology (41). Our study reports similar findings using a far
Figure 2. Individual results of triplicate ddPCR for each amplified gene.
Each line in the figure represents a patient. Each gene amplification was
performed in triplicate. Color was assigned to number of positive ddPCR
replicates for Helicobacter: Dark green color (3 positive replicates), light
green color (2 positive replicates), yellow color (one positive replicate), and
red color (zero positive replicates). DT, diagnostic tests; ddPCR, droplet
digital polymerase chain reaction.
Figure 3. H. pylori copies of genome equivalents detected by ddPCR in
dyspeptic patients. vacA s (blue), ureA (red), and 16S (green) bars. The
results are expressed as means 6 SEM: *P , 0.05/**P , 0.01/***P ,
0.005/****P,0.001 vs. 0DTHp(1).DT, diagnostic tests; ddPCR,droplet
digital polymerase chain reaction.
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more sensitive test such as ddPCR and adds support to the
various reports in the literature suggesting that undetectable
infection is not exceptional. For example, it is well-known that
antisecretory drugs or antibiotics may reduce the density of the
infection to levels undetectable by conventional tests; for this
reason, it is recommended that these drugs should be stopped in
theweeks before theDT are carried out (11). However, the use of
PPIs does not seem to explain the occurrence of “occult” in-
fection in this study. Patients were interviewed by telephone
before inclusion in the study and instructed to avoid PPIs and
antibiotics. On the day of endoscopy, patients were asked again
about PPI and antibiotic use before the urea breath test and the
endoscopy, and those who had not stopped the drugs were
excluded.
A limitation of our study is that the molecular tests were
performed on a single antral biopsy. It is well-known that
H. pylori can show a patchy distribution in the stomach, and the
more biopsies are performed, the higher the diagnostic accuracy
(42). However, the current cost of ddPCR limited the number of
biopsies that could be analyzed for each patient. Another limi-
tation is that because the samples we analyzed were negative by
conventional tests, we were unable to create a control group of
patients who were unequivocally negative.
At present, we still do not know the relevance of the “occult”
H. pylori infection. Conceivably, the low levels of infection may
be an advantage for these patients, protecting them from disease
by modulating the adjacent microbiome or the immune system.
Furthermore, the absence of active gastritis may suggest that
occult infection is associated with a lower risk of severe clinical
manifestations. However, other data suggest that patients with
occult H. pylori infection may present especially virulent or
resistant strains different from those found in high-density
infections (24). If so, it would be important to detect and treat
this unnoticed occult infection to prevent transmission, peptic
ulcer, and gastric cancer. Further studies are needed to char-
acterize low-density infection and to determine the factors that
modulate the bacterial load to prevent antibiotic resistances and
new infections.
In conclusion, ddPCR detected low-density “occult” H. pylori
infection in a significant proportion of dyspeptic patients di-
agnosed as negative by conventional methods. Digital PCR seems
to be more sensitive than histology and may be a very useful tool
for detecting Helicobacter in a subgroup of patients in whom the
infection is not identified by conventional methods.
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